The Pharma Reckoning: Can Drug Pricing Be Fixed Without Breaking Innovation?

The Question

Here is the specific prediction: will the United States reform drug pricing enough that major medicines cost no more than twice what Europeans pay for the same drug — by 2032? Our model gives this 42% probability. The anger is real and unprecedented. The Inflation Reduction Act of 2022 gave Medicare the ability to negotiate drug prices for the first time in its history. Public fury over healthcare costs has crossed a new threshold. Whether this moment produces genuine structural change, or gets absorbed by an industry that spent $370 million lobbying Congress in 2023 alone, is the central question.

The clearest illustration of the problem is Ozempic — the diabetes and weight-loss drug that has become a household name. In the US, a monthly supply costs around $1,000 without insurance. In Germany, the same drug costs about $150. In Canada, around $200. The drug was partly developed with public NIH funding. The company, Novo Nordisk, simply sets a different price in each market. Until recently, US law actually prohibited the government from negotiating drug prices on behalf of Medicare patients — the 50 million Americans on the government's elderly healthcare programme. That prohibition finally cracked in 2022. What happens next is what this article is about.

What the Evidence Shows

The Inflation Reduction Act is genuinely new ground. Medicare negotiated prices for ten major drugs in its first round, achieving reductions of 38% to 79% — not trivial. Insulin was separately capped at $35 a month for Medicare patients, ending one of the most egregious examples of price inflation: insulin was first developed in 1921, yet its list price had been ratcheting up for decades through minor reformulations and patent extensions. The list of negotiated drugs expands each year.

The system that inflates US drug prices has several levers. One is pay-to-delay: branded drug companies pay generic manufacturers not to launch cheaper versions, extending their market monopoly by years. Another is patent gaming — filing dozens of secondary patents on minor reformulations to block competition long after the original patent expires. A 2021 analysis found that every single one of the 210 drugs the FDA approved between 2010 and 2016 had received NIH funding before approval — totalling $230 billion in public investment. Taxpayers fund the research; companies set the price.

There is a quieter solution already working in the background: biosimilar drugs. When a biologic drug — a complex medicine made from living cells — comes off patent, cheaper copies called biosimilars can enter the market. In Europe, biosimilar uptake is high and prices fall sharply. In the US, uptake is sluggish because of complicated insurance arrangements, brand loyalty schemes, and prescriber inertia. Fixing this doesn't require new pricing legislation — it requires clearing bureaucratic barriers. That could save tens of billions of dollars without a single new law.

Why This Is Happening

The innovation argument is real but overstated. Drug companies argue that high US prices fund the R&D that produces new medicines, and that cutting prices kills innovation. There is some truth here. But the same companies consistently spend more on marketing and shareholder returns than on R&D. And the NIH funding data makes the argument uncomfortable: if taxpayers already fund the foundational research, why do they then pay the world's highest prices for the result?

The political moment is genuine but fragile. Drug pricing reform polls better than almost any other policy issue — Americans across the political spectrum support it. Yet it has been repeatedly defeated by lobbying. The IRA represents the first real crack in that wall. Whether Congress expands the negotiated drug list faster than the industry's lawyers can challenge it in court is the decisive question for the next six years.

The cultural mood has shifted. The Luigi Mangione case in late 2024 — in which a health insurance executive was murdered and the accused killer attracted public sympathy — was a jarring signal of how deep the anger runs. It didn't produce new legislation, but it crystallised a sentiment politicians can no longer easily ignore. That raises the cost of blocking reform, even if it doesn't guarantee it.

What Could Happen

What Can We Do

If you're a patient dealing with high drug costs right now, there are real options that don't require waiting for Congress. Most major drug companies run patient assistance programmes — Novo Nordisk's programme for Ozempic covers patients below 400% of the federal poverty line at no cost. Mark Cuban's Cost Plus Drugs platform sells hundreds of generic medications at manufacturing cost plus a small transparent markup, cutting prices dramatically. These are workarounds, not solutions. But they work for many people facing immediate financial hardship.

For policymakers, the most impactful short-term move — short of comprehensive reform — is fixing the biosimilar problem. The US gives biologic drugs 12 years of market exclusivity before cheaper copies can enter — the longest period among developed nations. Cutting that period could save tens of billions without the legal and political battle that direct price-setting triggers. The Federal Trade Commission has been aggressively pursuing pay-to-delay settlements; that enforcement should be expanded and properly funded.

For the drug industry itself, the most credible response to public fury is transparency. Publish what individual drugs actually cost to develop — not the industry-wide averages that are easy to manipulate. Several companies have started doing this voluntarily. If it became standard practice, the public conversation could finally be grounded in real numbers rather than competing claims — making it much harder to charge ten times what other countries pay and expect no one to notice.